U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H4O6
Molecular Weight 184.1031
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHELIDONIC ACID

SMILES

OC(=O)C1=CC(=O)C=C(O1)C(O)=O

InChI

InChIKey=PBAYDYUZOSNJGU-UHFFFAOYSA-N
InChI=1S/C7H4O6/c8-3-1-4(6(9)10)13-5(2-3)7(11)12/h1-2H,(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C7H4O6
Molecular Weight 184.1031
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Chelidonic acid (CA) is a γ-pyrone which is contained in the rhizome of Chelidonium majus L. It has multiple pharmacological effects including those of a mild analgesic, an antimicrobial, an oncostatic, a central nervous system sedative and the anti-inflammatory effect. Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test. Chelidonic acid administration significantly increased the mRNA expression of hippocampal estrogen receptor-β. The levels of hippocampal interleukin (IL)-1β, IL-6, and tumor necrosis factor-α were effectively attenuated by the administration of chelidonic acid. In addition, chelidonic acid significantly increased the levels of 5-hydroxytryptamine (serotonin), dopamine, and norepinephrine compared with those levels for the mice that were administered distilled water in the hippocampus. Chelidonic acid might serve as a new therapeutic strategy for the regulation of depression associated with inflammation.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.2 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Rats: In mast cell degranulation studies, ovalbumin immunized and challenged rats, chelidonic acid (1, 3 and 10mg/kg, i.p.) dose relatedly prevented ovalbumin challenge induced mast cell degranulation by differing degrees when compared with the vehicle-treated group, and these effects were comparable with prednisolone (10mg/kg).
Route of Administration: Intraperitoneal
In Vitro Use Guide
GAD was preincubated for 30 min with 1 mM chelidonic acid (CA), 5 mM glutamate (GLU), and 5 mM glutamate + 1 mM chelidonic acid (GLU + CA). Kinetic analysis showed that chelidonic acid was competitive with glutamate with a K; of 1.2 uM.
Substance Class Chemical
Record UNII
T33U4W5K6O
Record Status Validated (UNII)
Record Version